| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e43b4ca6b41ce9f54c9a895d474c81a |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 |
| filingDate |
2012-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77d619a3f13e1a814b6c4628975aaa53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a23f74e0735ddfdcbfd977b0d2bec455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25bd323dbcd2735206ca6f2383f646d4 |
| publicationDate |
2014-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2014034534-A |
| titleOfInvention |
Combination of HSP90 inhibitor and mTOR inhibitor |
| abstract |
Provided is an antitumor agent for combination therapy with an HSP90 inhibitor and another antitumor agent. An antitumor agent comprising a triazole compound represented by the following general formula (1) and an mTOR inhibitor. [Wherein, X represents a linear or branched alkyl group having 1 to 8 carbon atoms, an alkynyl group having 2 to 10 carbon atoms, or a halogen atom; Y represents a sulfur atom or an oxygen atom; An integer of 4 and A represents an amino group having a substituent] [Selection] Figure 1 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018502842-A |
| priorityDate |
2012-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |